Like Merck & Co.’s PAH drug Winrevair—which brought in $1.4 billion last year—35Pharma’s HS235 targets the activin receptor signalling pathway.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Like Merck & Co.’s PAH drug Winrevair—which brought in $1.4 billion last year—35Pharma’s HS235 targets the activin receptor signalling pathway.